Anthem Biosciences IPO: GMP, Price Band, Lot Size, Dates & Key Financial Details
Bengaluru-based contract research and manufacturing firm Anthem Biosciences Ltd has filed its Draft Red Herring Prospectus (DRHP) with SEBI, paving the way for its much-anticipated initial public offering (IPO). Backed by strong growth in the CDMO (Contract Development and Manufacturing Organization) sector, the IPO has garnered attention from institutional and retail investors alike.
IPO Timeline
While the exact IPO opening and closing dates are yet to be officially announced, market expectations suggest the IPO could hit the market in Q3 or Q4 2025, depending on SEBI’s approval and market conditions.
IPO Details
According to the DRHP:
Fresh Issue: ₹750 crore
Offer for Sale (OFS): Up to 1.46 crore equity shares by existing shareholders
Total Issue Size: Estimated at over ₹1,500 crore
Price Band & Lot Size (Tentative)
The company is yet to announce the price band, but market analysts speculate a range of ₹400–₹450 per share, subject to confirmation. The minimum lot size is expected to be in the range of 33–35 shares for retail investors.
About Anthem Biosciences
Founded in 2007, Anthem Biosciences is a leading CDMO offering services across drug discovery, development, and commercial manufacturing. The company operates from a large integrated R&D and manufacturing facility in Bengaluru and caters to global pharmaceutical and biotech companies.
It specializes in:
Active pharmaceutical ingredients (APIs)
Biologics
Analytical and formulation services
Financial Performance
Anthem Biosciences has reported strong financials:
FY23 Revenue: ₹1,107 crore (YoY growth of 32%)
FY23 PAT: ₹260 crore
EBITDA Margin: Over 25%
Its EBITDA and PAT margins reflect robust profitability and efficient cost control, making it an attractive bet for long-term investors.
Grey Market Premium (GMP)
As of now, no confirmed GMP is available, as the IPO dates and price band are not yet finalized. Once announced, GMP trends will offer better insight into investor sentiment.
Use of IPO Proceeds
The company plans to use the fresh issue proceeds for:
Capacity expansion of its R&D and manufacturing facilities
Working capital needs
Debt repayment
General corporate purposes
Book Running Lead Managers (BRLMs)
Top investment banks such as Kotak Mahindra Capital, Jefferies India, J.P. Morgan, and SBI Capital are acting as book-running lead managers for this IPO.
Conclusion
The Anthem Biosciences IPO is one to watch, especially given the growing global demand for CDMO services and the company’s solid financial track record. Investors looking for exposure to the pharmaceutical manufacturing sector may find this IPO a compelling opportunity.
